BIOMONTHLY injectable Pre Exposure Profilaxes (PrEP) has been found to be more effective than daily oral PrEP in preventing HIV acquisition among cisgender women, according to newly released interim results from the landmark HPTN 084 study. According to the study, cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP). The early study unblinding for superior efficacy in this prevention trial in women follows results reported earlier this year from a companion study (HPTN 083) that also established long-acting cabotegravir’s superiority to daily oral PrEP in preventing…
Read MoreBimonthly Injectable PrEP More Effective Than Daily Oral PrEP- New Study
